Budesonide Foam for Ulcerative Colitis Patients Experiencing Inadequate Response to Biological Therapy
BACKGROUND In recent years, a plethora of therapeutic agents for ulcerative colitis (UC), especially novel biologics (Bio), have become available. Although it is now possible to use biological drugs, there should be no need for frequently changing medications. To avoid first-pass metabolism in the liver, thus reducing systemic bioavailability, budesonide foam has been applied as a topical steroid. We therefore evaluated whether budesonide foam has therapeutic value in UC patients who responded inadequately to Bio or to tacrolimus. MATERIAL AND METHODS We enrolled 10 patients who were experiencing an inadequate response to Bio (n=7) or to tacrolimus (n=3) at Juntendo University. We used Lichtiger's index to assess UC activity and clinical response. RESULTS Of the study patients, 4 were receiving adalimumab, 3 golimumab, and 3 tacrolimus. The average Lichtiger's index before budesonide administration was 7.1 (range 13-3), which improved to 3.4 (range 7-0) after budesonide therapy (p=0.01). Notably, 4 of the 6 cases with a Lichtiger's index >4 before budesonide administration achieved improvement of ≥3 points or remission. CONCLUSIONS Although the number of patients was small, budesonide foam had significant efficacy when added to the treatment of patients having an inadequate response to Bio or to tacrolimus. These results suggest that in cases responding poorly to Bio, adding budesonide foam as combination therapy can achieve a clinical remission.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Medical science monitor : international medical journal of experimental and clinical research - 25(2019) vom: 22. Dez., Seite 9855-9863 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shibuya, Tomoyoshi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
51333-22-3 |
|---|
| Anmerkungen: |
Date Completed 26.06.2020 Date Revised 26.06.2020 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.12659/MSM.918562 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM304658286 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM304658286 | ||
| 003 | DE-627 | ||
| 005 | 20231225115444.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.12659/MSM.918562 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1015.xml |
| 035 | |a (DE-627)NLM304658286 | ||
| 035 | |a (NLM)31865359 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shibuya, Tomoyoshi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Budesonide Foam for Ulcerative Colitis Patients Experiencing Inadequate Response to Biological Therapy |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.06.2020 | ||
| 500 | |a Date Revised 26.06.2020 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND In recent years, a plethora of therapeutic agents for ulcerative colitis (UC), especially novel biologics (Bio), have become available. Although it is now possible to use biological drugs, there should be no need for frequently changing medications. To avoid first-pass metabolism in the liver, thus reducing systemic bioavailability, budesonide foam has been applied as a topical steroid. We therefore evaluated whether budesonide foam has therapeutic value in UC patients who responded inadequately to Bio or to tacrolimus. MATERIAL AND METHODS We enrolled 10 patients who were experiencing an inadequate response to Bio (n=7) or to tacrolimus (n=3) at Juntendo University. We used Lichtiger's index to assess UC activity and clinical response. RESULTS Of the study patients, 4 were receiving adalimumab, 3 golimumab, and 3 tacrolimus. The average Lichtiger's index before budesonide administration was 7.1 (range 13-3), which improved to 3.4 (range 7-0) after budesonide therapy (p=0.01). Notably, 4 of the 6 cases with a Lichtiger's index >4 before budesonide administration achieved improvement of ≥3 points or remission. CONCLUSIONS Although the number of patients was small, budesonide foam had significant efficacy when added to the treatment of patients having an inadequate response to Bio or to tacrolimus. These results suggest that in cases responding poorly to Bio, adding budesonide foam as combination therapy can achieve a clinical remission | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Glucocorticoids |2 NLM | |
| 650 | 7 | |a Budesonide |2 NLM | |
| 650 | 7 | |a 51333-22-3 |2 NLM | |
| 650 | 7 | |a golimumab |2 NLM | |
| 650 | 7 | |a 91X1KLU43E |2 NLM | |
| 650 | 7 | |a Adalimumab |2 NLM | |
| 650 | 7 | |a FYS6T7F842 |2 NLM | |
| 650 | 7 | |a Tacrolimus |2 NLM | |
| 650 | 7 | |a WM0HAQ4WNM |2 NLM | |
| 700 | 1 | |a Nomura, Kei |e verfasserin |4 aut | |
| 700 | 1 | |a Okahara, Koki |e verfasserin |4 aut | |
| 700 | 1 | |a Haga, Keiichi |e verfasserin |4 aut | |
| 700 | 1 | |a Nomura, Osamu |e verfasserin |4 aut | |
| 700 | 1 | |a Murakami, Takashi |e verfasserin |4 aut | |
| 700 | 1 | |a Uchida, Shino |e verfasserin |4 aut | |
| 700 | 1 | |a Kodani, Tomohiro |e verfasserin |4 aut | |
| 700 | 1 | |a Ishikawa, Dai |e verfasserin |4 aut | |
| 700 | 1 | |a Sakamoto, Naoto |e verfasserin |4 aut | |
| 700 | 1 | |a Ogihara, Tatsuo |e verfasserin |4 aut | |
| 700 | 1 | |a Osada, Taro |e verfasserin |4 aut | |
| 700 | 1 | |a Nagahara, Akihito |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medical science monitor : international medical journal of experimental and clinical research |d 1997 |g 25(2019) vom: 22. Dez., Seite 9855-9863 |w (DE-627)NLM09549491X |x 1643-3750 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2019 |g day:22 |g month:12 |g pages:9855-9863 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.12659/MSM.918562 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2019 |b 22 |c 12 |h 9855-9863 | ||